# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 91-100 of 563 results.
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Status: Not yet recruiting
Last Changed: Jul 07, 2020
First Received: Jul 07, 2020
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Zanubrutinib, Lenalidomide and Rituximab (ZR2)
Locations: Shanghai Ruijin Hospital, Shanghai, Shanghai, China
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Status: Not yet recruiting
Last Changed: Jul 02, 2020
First Received: Jul 02, 2020
Disease(s): Diffuse Large B-Cell Lymphoma (DLBCL)
Intervention(s): Tisagenlecleucel
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Jun 25, 2020
First Received: Oct 07, 2015
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation
Locations: University of Nebraska Medical Center, Omaha, Nebraska, United States
Memoral Sloan Kettering Basking Ridge (Consent and Follow-Up Only), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Consent and Follow up Only), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Consent and Follow Up Only), Montvale, New Jersey, United States
Memorial Sloan Kettering Commack (Consent and Follow-up Only), Commack, New York, United States
... and 10 other locations.
A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
Status: Recruiting
Last Changed: Feb 01, 2019
First Received: Feb 23, 2017
Disease(s): B-cell Lymphoma
Intervention(s): AC0010MA
Locations: Peking Union Medical College Hospital, Beijing, Beijing, China
The First Affiliated Hospital,Zhejiang University, Hangzhou, Zhejiang, China
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jan 09, 2020
First Received: Jan 16, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Ibrutinib Oral Capsule [Imbruvica], R-CHOEP chemotherapy
Locations: Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
Status: Recruiting
Last Changed: Sep 15, 2017
First Received: Sep 13, 2017
Disease(s): B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
Intervention(s): PZ01 CAR-T cells
Locations: Department of Hematology, Navy General Hospital of PLA, Beijing, Beijing, China
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Mar 06, 2020
First Received: Mar 05, 2020
Disease(s): B-cell Non-Hodgkin Lymphoma
Intervention(s): Welgenaleucel
Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
Status: Recruiting
Last Changed: Aug 06, 2019
First Received: Apr 26, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Ibrutinib and Bortezomib + R-CHOP
Locations: Charité - Universitätsmedizin Berlin, Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum, Berlin, Germany
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
Status: Not yet recruiting
Last Changed: Apr 21, 2020
First Received: Apr 03, 2020
Disease(s): DLBCL, Diffuse Large B Cell Lymphoma
Intervention(s): R-pola-mini-CHP, R-mini-CHOP
Locations: Department og Hematology, Aalborg University Hospital, Aalborg, Denmark
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
Clinic of Hematology L-4241, Rigshospitalet, Copenhagen, Denmark
Sydvestjysk Sygehus, Esbjerg, Denmark
Herlev Hospital, Herlev, Denmark
... and 42 other locations.
CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: May 13, 2020
First Received: Sep 19, 2017
Disease(s): Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, DLBCL
Intervention(s): AUTO3
Locations: City of Hope Hospital, Duarte, California, United States
Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center/Sarah Cannon Research Institute, Denver, Colorado, United States
Sylvester Comprehensive Cancer Center / University of Miami, Miami, Florida, United States
Siteman Cancer Center / Washington University School of Medicine, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
... and 7 other locations.